What does this research mean for the field?

T2-low asthma is a mechanistically diverse and heterogeneous clinical construct that currently lacks validated positive biomarkers and relies on exclusionary definitions and treatable-traits care. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize current clinical definitions, underlying molecular pathways, biomarker limitations, and evidence-graded therapeutic approaches for heterogeneous T2-low asthma.

August 22, 2026Journal of Asthma

T2-Low Asthma: Mechanistic Pathways, Biomarkers, and Emerging Therapeutic Strategies

View Full Paper

Ask AI

Bookmark

To synthesize current clinical definitions, underlying molecular pathways, biomarker limitations, and evidence-graded therapeutic approaches for heterogeneous T2-low asthma.
Searched PubMed/MEDLINE, Embase, and the Cochrane Library from database inception through June 2026.
Prioritized peer-reviewed human randomized trials, systematic reviews, severe-asthma registries, and biomarker cohorts, synthesizing 63 total references.
T2-low asthma remains an exclusionary diagnosis defined by low blood/sputum eosinophils and low fractional exhaled nitric oxide, encompassing neutrophilic, paucigranulocytic, obesity-linked, and remodeling-dominant phenotypes.
Candidate mechanistic drivers include Th1/Th17 signaling, CXCL8/CXCR2-driven neutrophil recruitment, inflammasome activation, IL-6-associated inflammation, epithelial alarmins, and dysbiosis.
No positive biomarker currently identifies treatment-responsive disease in routine practice, leaving management dependent on optimized inhalers, treatable traits, and selective therapies such as tezepelumab, azithromycin, or bronchial thermoplasty.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Narrative review demonstrates mechanistic heterogeneity and biomarker deficits in T2-low asthma, indicating the need for targeted phenotyping and trial designs.

Cite This Study

Barkas et al. (2026) studied this question.

synapsesocial.com/papers/6a895f87ca7ade938187e353 https://doi.org/10.1080/02770903.2026.2721176

View Full Paper

Ask AI

Bookmark

Implication

Narrative review demonstrates mechanistic heterogeneity and biomarker deficits in T2-low asthma, indicating the need for targeted phenotyping and trial designs.

T2-Low Asthma: Mechanistic Pathways, Biomarkers, and Emerging Therapeutic Strategies

Key Points

Discussion

Implication

Cite This Study

T2-Low Asthma: Mechanistic Pathways, Biomarkers, and Emerging Therapeutic Strategies

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider